Study to determine if a DNA-based blood test can help detect cancer predisposition in NF1 patients

The Children’s Tumor Foundation (CTF) has announced a groundbreaking 3-year study, which it will fund for nearly $2 million, to determine if a DNA-based blood test can offer better understanding and ultimately earlier diagnosis of cancer predisposition in neurofibromatosis type 1 (NF1) patients.

Related Keywords

Annette Bakker ,Angela Hirbe ,Jack Shern ,Emily Henderson ,John Shern ,Washington University ,National Cancer Institute ,Department Of Defense ,National Institutes Of Health ,Research Programs ,Nf Clinical Trials Consortium ,Children Tumor Foundation ,Tumor Foundation ,Principal Investigators ,National Institutes ,Aadel Chaudhuri ,Idea Award ,Discovery Industry Focus ,Capitol Hill ,Biomarker ,Dancer ,Flood ,Blood Test ,Children ,Na ,Alignant ,Medical Research ,Nerve ,Neurofibromatosis ,Research ,Humor ,